Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling

Antisense oligonucleotide (AON) therapeutics offer new avenues to pursue clinically relevant targets inaccessible with other technologies. Advances in improving AON affinity and stability by incorporation of high affinity nucleotides, such as locked nucleic acids (LNA), have sometimes been stifled b...

Descripción completa

Detalles Bibliográficos
Autores principales: Moisan, Annie, Gubler, Marcel, Zhang, Jitao David, Tessier, Yann, Dumong Erichsen, Kamille, Sewing, Sabine, Gérard, Régine, Avignon, Blandine, Huber, Sylwia, Benmansour, Fethallah, Chen, Xing, Villaseñor, Roberto, Braendli-Baiocco, Annamaria, Festag, Matthias, Maunz, Andreas, Singer, Thomas, Schuler, Franz, Roth, Adrian B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363415/
https://www.ncbi.nlm.nih.gov/pubmed/28325303
http://dx.doi.org/10.1016/j.omtn.2016.11.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363415/
https://www.ncbi.nlm.nih.gov/pubmed/28325303
http://dx.doi.org/10.1016/j.omtn.2016.11.006

Ejemplares similares